Novo Nordisk Stock Could Surge 52% Here’s Why
Novo Nordisk (NYSE:NVO) is facing challenges following its guidance cut, but its blockbuster drugs, Ozempic and Wegovy, continue to drive strong sales growth. Analysts see a 52% upside potential with a $70 target, signaling this pharma giant’s pullback could be a rare buying opportunity. Stock prices used were the market prices of Nov. 10, 2025. … Read more